Since outcomes of refractory and relapsed AML patients are consistently disappointing, novel therapeutic approaches are warranted and CD47-SIRPα blockade has emerged as a possible novel therapeutic strategy. The gene discussed is CD47; the disease is acute myeloid leukemia.